Welcome to our dedicated page for ANEW MEDICAL SEC filings (Ticker: WENA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to decode ANEW MEDICAL, INC.’s dense clinical disclosures on the Klotho gene? Early-stage biotech filings often span hundreds of pages of technical data, trial protocols, and complex risk factors. Missing a single paragraph could mean overlooking a pivotal FDA update or a sudden shift in cash burn.
Stock Titan’s AI bridges that gap. Our platform ingests every ANEW MEDICAL annual report 10-K simplified, each ANEW MEDICAL quarterly earnings report 10-Q filing, and every ANEW MEDICAL 8-K material events explained notice the moment they appear on EDGAR. Then we deliver concise, plain-English summaries that spotlight Klotho research milestones, R&D spending trends, and pending patent expirations—so you don’t need a PhD to follow the story.
Wondering about management’s conviction? Track ANEW MEDICAL insider trading Form 4 transactions in real time. Our dashboard flags ANEW MEDICAL executive stock transactions Form 4 within minutes, alerting you to insider buying before the market reacts. Need governance details? The latest ANEW MEDICAL proxy statement executive compensation is broken down into clear charts that compare cash bonuses to pipeline progress. For quick context, our AI also attaches peer benchmarks and historical trends to each section.
Whether you’re asking “ANEW MEDICAL SEC filings explained simply” or seeking an ANEW MEDICAL earnings report filing analysis, every document—10-K, 10-Q, S-1, or 13D—sits one click away with searchable text, key-point highlights, and exportable tables. Stop skimming PDFs and start making informed decisions with AI-powered clarity.
ANEW Medical, Inc. (WENA) completed a business combination and began Nasdaq trading after receiving net cash proceeds of approximately $181,339 related to the merger and related PIPE financings. The merger consideration included 6,000,000 shares valued at $60.0 million (implied $10 per share) and contingent consideration of 2,000,000 shares subject to share-price triggers. The company reported recurring losses, negative operating cash flows, an accumulated deficit of about $16.9 million, and stated there is substantial doubt about its ability to continue as a going concern for 12 months without additional funding. For the three and six months ended June 30, 2025, material items disclosed include net loss per share of $(0.12) and $(0.21) in comparative periods, weighted average common shares outstanding of 33,952,418 (three months) and 30,755,807 (six months) for 2025 vs 15,678,898 in comparable 2024 periods, representative warrant liabilities of $132,447 (June 30, 2025), and significant non-cash share-based compensation and warrant fair value changes. The company holds intangible license and patent assets (licenses totaling $2,251,134 across categories) and disclosed multiple convertible notes, financings, and conversions into common stock during the periods presented.
Klotho Neurosciences, Inc. submitted a Form 12b-25 notifying the SEC that its Quarterly Report for the period ended June 30, 2025 could not be filed on time because the financial statements were not completed in time to obtain necessary review and signatures. The company indicated it is relying on Rule 12b-25(b) and expects to file the report within the prescribed 15-calendar-day relief period. The filing states that other periodic reports have been filed and the company does not anticipate a significant change in results for the period.
Klotho Neurosciences entered a Letter Agreement with AAVnerGene to manufacture and develop its KLTO-202 gene therapy candidate using AAVnerGene platform technology. The Company will pay an initial fee of $250,000, additional fees tied to clinical trial stages, and a 2% royalty on revenue from products created using the referenced platform. The agreement is filed as an exhibit to the 8-K and the company furnished a related press release.
The filing discloses the commercial terms but does not quantify expected costs, timelines, or projected revenue impact; it includes customary forward-looking statement cautions.
Shalom Hirschman, identified as a director of Klotho Neurosciences, Inc. (KLTO), reported receiving 70,149 shares of common stock on 08/05/2025 as contingent merger consideration. The Form 4 shows the acquisition was recorded as an acquisition (code A) and the filing was signed on 08/07/2025.
Following the reported transaction, Mr. Hirschman's reported beneficial ownership increased to 558,873 shares, held directly. The filing lists his Charlotte, NC address and identifies his relationship to the issuer as a director.
Klotho Neurosciences director Riad El-Dada reported the acquisition of 10,000 non-qualified stock options on 08/07/2025 with an exercise price of $0.41. The options are stated to be fully vested and exercisable immediately and carry an expiration date of 01/16/2035. After this transaction, the reporting person beneficially owns 40,000 derivative securities related to common stock, held directly.
The Form 4 discloses only this option acquisition and the immediate exercisability; no cash exercises, sales, or other transactions are reported in the filing.
Form 4 filing for Klotho Neurosciences, Inc. (KLTO) by Joseph Sinkule, CEO and Director. The filing reports two transactions: on 07/22/2025 and 08/05/2025 the Reporting Person transferred and pledged a total of 2,000,000 common shares to Stock Loan Solutions, LLC as collateral for a non-recourse, 3-year term loan. The lender may take actions with respect to the pledged shares, including selling, transferring, hedging, or creating and trading derivatives.
The report shows 4,446,700 shares beneficially owned following the 08/05/2025 transaction, which includes 1,000,000 shares issuable on incentive option exercise and 537,180 shares received as contingent merger consideration. The Reporting Person retains a conditional right to vote the pledged shares absent default; lender must transfer shares back within five business days of repayment, subject to setoff rights.
Form 4 filed 08/07/2025 shows director Jon McGarity increased his stake in Klotho Neurosciences, Inc. (ticker stated: KLTO) via two equity-boosting transactions.
- Common stock: 14,641 shares acquired on 08/05/2025 as contingent merger consideration, lifting direct ownership to 46,636 shares.
- Stock options: Grant of 10,000 fully-vested non-qualified options exercisable at $0.41, expiring 01/16/2035. Insider now holds 40,000 derivative securities.
All reported activity represents acquisitions; no shares were sold. Equity is held directly, though underlying common shares are beneficially owned through the Jon W. McGarity & Susan A. McGarity Revocable Trust. The filing contains no financial performance data or market prices.
Samuel Zentman, a director of Klotho Neurosciences, Inc. (KLTO), reported insider acquisitions and option holdings on Form 4. On 08/05/2025 he received 153,494 common shares as contingent merger consideration and, after the transaction, beneficially owned 736,440 common shares. The filing notes some shares are owned by The Samuel Zentman 2012 Irrevocable Trust, which Zentman beneficially owns.
On 08/07/2025 Zentman acquired a non-qualified stock option with an exercise price of $0.41 for 10,000 options and the filing reports 40,000 derivative securities beneficially owned following the transaction. The options are fully vested and exercisable at any time, and the filings identify an expiration date of 01/16/2035 for the derivative instrument shown.
Form 4 filed 08/07/2025 – Klotho Neurosciences, Inc. (KLTO)
Chief Financial Officer Jeffrey Brian LeBlanc disclosed the acquisition of 156,199 common shares on 08/05/2025. The shares were received as contingent merger consideration, not through an open-market purchase. After the transaction, LeBlanc’s direct beneficial ownership rises to 720,342 shares; no derivative positions were reported.
- Transaction code: A (acquired)
- Ownership form: Direct
- No price or derivative activity disclosed
The filing strengthens insider equity alignment but stems from pre-arranged merger terms rather than discretionary buying, limiting immediate market impact.
FAQ
What is the current stock price of ANEW MEDICAL (WENA)?
What is the market cap of ANEW MEDICAL (WENA)?
